Zealand Pharma to participate in the Jefferies Global Healthcare Conference
Press release – No. 16 / 2025
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
Copenhagen, Denmark, November 12, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London at 10:30am GMT (11:30am CET) on Wednesday, November 19, 2025.
A live audio webcast of the fireside chat will be available at , and accessible through the company’s website at , where a recording of the webcast will also be archived after the event.
About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit .
Contacts
Adam Lange (Investors)
Vice President, Investor Relations
Zealand Pharma
Email:
Neshat Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email:
Rachel James-Owens (Media)
Vice President, Corporate Communications & Media Relations
Zealand Pharma
Email:
